Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorNIDEGGER, Ines
dc.contributor.authorMACEY, Julie
dc.contributor.authorFEREY, Marine
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSINGIER, Allison
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorTOURNIER, Marie
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPERINO, Justine
ORCID: 0000-0003-0039-0734
IDREF: 254309690
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSALVO, Francesco
dc.date.accessioned2024-12-09T09:57:02Z
dc.date.available2024-12-09T09:57:02Z
dc.date.issued2024-10-14
dc.identifier.issn1873-5010en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/203787
dc.description.abstractEnBACKGROUND: A highly effective therapy involving elexacaftor, tezacaftor, and ivacaftor (ETI) for cystic fibrosis (CF) patients has recently raised safety concerns regarding potential psychiatric disorders. The manuscript reports cases of suicide attempts in patients receiving ETI and investigates putative causality using the WHO spontaneous reporting database. METHODS: First, four cases of suicide attempts/self-injury are described. Second, a disproportionality analysis was conducted using spontaneous reports collected in Vigibase through the standardised MedDRA Query (narrow version) "Suicide/Self-injury" and ETI exposure. Reporting Odds Ratio (ROR) was calculated for the main and subgroup (i/suicide attempt, ii/suicidal ideation) analyses. Sensitivity analyses were performed with variations in exposure, to ivacaftor/lumacaftor to assess the intrinsic psychiatric risk of CF patients, and paracetamol as a positive control for suicide attempt and a negative one for suicidal ideation. Exposure to reduced-dose ETI was studied to evaluate the dose-gradient effect. RESULTS: Four cases of suicide attempt/self-injury occurred 3 to 13 months after ETI initiation in CF patients and were reported to the Bordeaux Pharmacovigilance centre. Aside, in Vigibase, ETI is associated with an increased likelihood of reporting suicidal behaviour (ROR 2.5, 95 % CI[2.1; 2.8]). A signal of disproportionate reporting was found for the subgroup of suicide attempts (1.4, 95 % CI[1.2; 1.8]), unlike ivacaftor/lumacaftor, which was associated only with the risk of reporting suicidal ideation. Significant ROR values were also found for reduced-dose ETI for all psychiatric effects studied except suicide attempt. CONCLUSIONS: ETI exposure is related with increased reporting of suicidal behaviour. A potential dose-dependent effect merits further investigation.
dc.language.isoENen_US
dc.subject.enAttempted
dc.subject.enCystic fibrosis
dc.subject.enDrug-related side effects and adverse reactions
dc.subject.enEpidemiology
dc.subject.enPharmacovigilance
dc.subject.enPsychiatry
dc.subject.enSuicide
dc.title.enSuicidal behaviour and CFTR modulators: A case series and WHO database disproportionality analysis
dc.title.alternativeJ Cyst Fibrosen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.jcf.2024.09.020en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed39406576en_US
bordeaux.journalJournal of Cystic Fibrosisen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04826466
hal.version1
hal.date.transferred2024-12-09T09:57:05Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Cystic%20Fibrosis&rft.date=2024-10-14&rft.eissn=1873-5010&rft.issn=1873-5010&rft.au=NIDEGGER,%20Ines&MACEY,%20Julie&FEREY,%20Marine&SINGIER,%20Allison&TOURNIER,%20Marie&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée